Biopharmas

For decades, the pharmaceutical industry’s approach to mental health has been a model of conservative, incremental innovation. The market was saturated with medications for me, too—mild variations of existing antidepressants and antipsychotics that offered modest, predictable returns. For investors, it was a safe bet. For patients suffering from the most severe forms of mental illness, […]